Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

AI catches one-third of interval breast cancers missed at screening

2.

Novel Psychedelic Promising on Resistant Depression

3.

Colon cancer and exercise: Can physical activity reprogram genes?

4.

Research suggests peer support may lower depression, stress among cancer patients in low-resource settings

5.

FDA Expands Use of T-DXd in Early HER2+ Breast Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot